AIM: To examine cytokeratin-18 (CK-18) and caspase-cleaved CK-18 expression in tumours and correlate with clinicopathological outcomes including tumour regression grade (TRG) response. METHODS: Formalin-fixed human gastro-oesophageal cancers were constructed into tissue microarrays. The first set consisted of 122 gastric/gastro-oesophageal cancer cases not exposed to neoadjuvant chemotherapy and the second set consisted of 97 gastric/gastro-oesophageal cancer cases exposed to pre-operative platinum-based chemotherapy. Expression of CK-18 and caspase-cleaved CK-18 was investigated using immunohistochemistry. RESULTS: CK18 was commonly expressed in gastro-oesophageal tumours (92.6%). Fifty-six point seven percent of tumours previously exposed to neoadjuvant chemotherapy were positive for caspase-cleaved CK-18 expression compared to only 24.6% of tumours not previously exposed to neoadjuvant chemotherapy (P = 0.009). In patients who received neoadjuvant chemotherapy, caspase-cleaved cytokeratin-18 expression correlated with favourable TRG response (TRG 1, 2 or 3, P = 0.043). CONCLUSION: This is the largest study to date of CK-18 and caspase-cleaved CK-18 expression in gastro-oesophageal tumours. We provide the first evidence that caspase-cleaved CK-18 predicts tumour regression with neoadjuvant chemotherapy.
AIM: To examine cytokeratin-18 (CK-18) and caspase-cleaved CK-18 expression in tumours and correlate with clinicopathological outcomes including tumour regression grade (TRG) response. METHODS:Formalin-fixed humangastro-oesophageal cancers were constructed into tissue microarrays. The first set consisted of 122 gastric/gastro-oesophageal cancer cases not exposed to neoadjuvant chemotherapy and the second set consisted of 97 gastric/gastro-oesophageal cancer cases exposed to pre-operative platinum-based chemotherapy. Expression of CK-18 and caspase-cleaved CK-18 was investigated using immunohistochemistry. RESULTS:CK18 was commonly expressed in gastro-oesophageal tumours (92.6%). Fifty-six point seven percent of tumours previously exposed to neoadjuvant chemotherapy were positive for caspase-cleaved CK-18 expression compared to only 24.6% of tumours not previously exposed to neoadjuvant chemotherapy (P = 0.009). In patients who received neoadjuvant chemotherapy, caspase-cleaved cytokeratin-18 expression correlated with favourable TRG response (TRG 1, 2 or 3, P = 0.043). CONCLUSION: This is the largest study to date of CK-18 and caspase-cleaved CK-18 expression in gastro-oesophageal tumours. We provide the first evidence that caspase-cleaved CK-18 predicts tumour regression with neoadjuvant chemotherapy.
Authors: Jeffrey Cummings; Cassandra Hodgkinson; Rajesh Odedra; Patrizia Sini; Simon P Heaton; Kirsten E Mundt; Tim H Ward; Robert W Wilkinson; Jim Growcott; Andrew Hughes; Caroline Dive Journal: Mol Cancer Ther Date: 2008-03 Impact factor: 6.261
Authors: A M Mandard; F Dalibard; J C Mandard; J Marnay; M Henry-Amar; J F Petiot; A Roussel; J H Jacob; P Segol; G Samama Journal: Cancer Date: 1994-06-01 Impact factor: 6.860
Authors: K R Fareed; A Al-Attar; I N Soomro; P V Kaye; J Patel; D N Lobo; S L Parsons; S Madhusudan Journal: Br J Cancer Date: 2010-05-11 Impact factor: 7.640
Authors: Khaleel R Fareed; Mohammad Ilyas; Philip V Kaye; Irshad N Soomro; Dileep N Lobo; Simon L Parsons; Srinivasan Madhusudan Journal: Histopathology Date: 2009-10 Impact factor: 5.087
Authors: Katarina Kolostova; Rafal Matkowski; Robert Gürlich; Krzysztof Grabowski; Katarzyna Soter; Robert Lischke; Jan Schützner; Vladimir Bobek Journal: Cytotechnology Date: 2015-04-11 Impact factor: 2.058
Authors: R Kennedy; D Kuvshinov; A Sdrolia; E Kuvshinova; K Hilton; S Crank; A W Beavis; V Green; J Greenman Journal: Sci Rep Date: 2019-04-19 Impact factor: 4.379
Authors: Shereen El Mashed; Tracey R O'Donovan; Elaine Kay; Anthony O'Grady; Damian McManus; Richard C Turkington; Sharon L McKenna Journal: BMC Cancer Date: 2022-08-20 Impact factor: 4.638